Core Insights - HYTN Innovations Inc. has received its first purchase order and import permit for GMP cannabis vape cartridges, marking a significant milestone for the company [1][2] - The initial order consists of 1,000 one-gram live resin vape cartridges, which will be manufactured in compliance with GMP standards and exported to the UK, pending regulatory approvals [2] - The company emphasizes its commitment to quality and safety in its pharmaceutical-grade cannabis offerings, aiming to serve regulated international markets [2][3] Company Overview - HYTN Innovations Inc. specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids [4] - The company aims to become a premier provider of these products across federally regulated markets by identifying market opportunities and innovating product development [4] GMP Compliance - Good Manufacturing Practices (GMP) guidelines ensure that manufactured products are safe for human consumption, and many countries require adherence to these standards [5] - The company's compliance with GMP standards is crucial for its operations and international market access [2][3]

TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those territories. ...